Astellas Pharma still looks to grow in cancer with a pipeline that includes internally developed programs that could stand out in oncology. But the drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguci said.
The post Astellas Exec Talks Dealmaking and Pipeline Strategy in Cancer, Gene Therapy & More appeared first on MedCity News.
